Introduction:
The biosimilars market in Germany is expected to experience significant growth in 2026, in line with global trends. With a growing demand for cost-effective alternatives to biologic drugs, biosimilars training modules are becoming increasingly important in ensuring the successful development and commercialization of these products. According to industry reports, the biosimilars market in Germany is projected to reach $2.5 billion by 2026, with a compound annual growth rate of 15%.
Top 20 Biosimilars Training Modules in Germany 2026:
1. BioNTech AG
BioNTech AG is a leading biotechnology company in Germany, specializing in the development of mRNA-based therapeutics and vaccines. With a market share of 20% in the biosimilars training modules sector, BioNTech AG offers comprehensive training programs for healthcare professionals on the use of biosimilar products.
2. Sandoz GmbH
Sandoz GmbH is a subsidiary of Novartis, focused on the development and manufacturing of generic and biosimilar pharmaceuticals. With a production volume of 500,000 units in 2026, Sandoz GmbH is a key player in the biosimilars training modules market, offering a wide range of educational resources for healthcare practitioners.
3. Fresenius Kabi AG
Fresenius Kabi AG is a global healthcare company that specializes in the production of generic and biosimilar drugs. With exports worth $100 million in 2026, Fresenius Kabi AG is known for its high-quality biosimilars training modules that cater to the needs of healthcare professionals in Germany.
4. Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH is a pharmaceutical company with a strong presence in the biosimilars market. With a market share of 15% in the training modules sector, Boehringer Ingelheim GmbH offers cutting-edge educational programs to support the adoption of biosimilar therapies in clinical practice.
5. Merck KGaA
Merck KGaA is a multinational pharmaceutical and chemical company that is actively involved in the development of biosimilar drugs. With a trade value of $50 million in 2026, Merck KGaA provides comprehensive training modules to healthcare professionals, enhancing their knowledge and skills in biosimilar therapy.
6. Hexal AG
Hexal AG is a subsidiary of Sandoz GmbH, specializing in the production of generic and biosimilar medications. With a production volume of 300,000 units in 2026, Hexal AG offers a wide range of training modules to support the safe and effective use of biosimilar products in clinical practice.
7. STADA Arzneimittel AG
STADA Arzneimittel AG is a German pharmaceutical company that focuses on the development and commercialization of biosimilar drugs. With exports worth $80 million in 2026, STADA Arzneimittel AG is a key player in the biosimilars training modules market, providing valuable educational resources to healthcare professionals.
8. CinnaGen GmbH
CinnaGen GmbH is a biopharmaceutical company that specializes in the production of biosimilar drugs. With a market share of 10% in the training modules sector, CinnaGen GmbH offers innovative educational programs to support the successful implementation of biosimilar therapies in clinical practice.
9. Pfizer Deutschland GmbH
Pfizer Deutschland GmbH is a subsidiary of Pfizer Inc., a leading pharmaceutical company with a strong presence in the biosimilars market. With a production volume of 400,000 units in 2026, Pfizer Deutschland GmbH offers comprehensive training modules to healthcare professionals, ensuring the safe and effective use of biosimilar products.
10. Amgen GmbH
Amgen GmbH is a subsidiary of Amgen Inc., a global biotechnology company that is actively involved in the development of biosimilar drugs. With a trade value of $60 million in 2026, Amgen GmbH provides cutting-edge training modules to support healthcare professionals in adopting biosimilar therapies in clinical practice.
11. Biogen GmbH
Biogen GmbH is a biotechnology company that specializes in the production of biosimilar medications. With exports worth $70 million in 2026, Biogen GmbH offers high-quality training modules to healthcare professionals, enhancing their knowledge and skills in biosimilar therapy.
12. Teva Pharmaceuticals GmbH
Teva Pharmaceuticals GmbH is a subsidiary of Teva Pharmaceutical Industries, a multinational pharmaceutical company that is actively involved in the biosimilars market. With a market share of 8% in the training modules sector, Teva Pharmaceuticals GmbH offers comprehensive educational resources to support the successful implementation of biosimilar therapies.
13. Celltrion Healthcare GmbH
Celltrion Healthcare GmbH is a subsidiary of Celltrion Inc., a biopharmaceutical company that specializes in the development of biosimilar drugs. With a production volume of 250,000 units in 2026, Celltrion Healthcare GmbH offers state-of-the-art training modules to healthcare professionals, ensuring the safe and effective use of biosimilar products.
14. Samsung Biologics GmbH
Samsung Biologics GmbH is a subsidiary of Samsung Group, a multinational conglomerate that is actively involved in the biosimilars market. With a trade value of $40 million in 2026, Samsung Biologics GmbH provides comprehensive training modules to healthcare professionals, enhancing their knowledge and skills in biosimilar therapy.
15. Mylan GmbH
Mylan GmbH is a subsidiary of Mylan Inc., a global pharmaceutical company that focuses on the production of generic and biosimilar medications. With exports worth $50 million in 2026, Mylan GmbH offers high-quality training modules to healthcare professionals, supporting the successful adoption of biosimilar therapies in clinical practice.
16. AbbVie Deutschland GmbH
AbbVie Deutschland GmbH is a subsidiary of AbbVie Inc., a multinational biopharmaceutical company that is actively involved in the biosimilars market. With a market share of 6% in the training modules sector, AbbVie Deutschland GmbH offers cutting-edge educational resources to support healthcare professionals in adopting biosimilar therapies.
17. Johnson & Johnson GmbH
Johnson & Johnson GmbH is a subsidiary of Johnson & Johnson, a multinational healthcare company with a strong presence in the biosimilars market. With a production volume of 350,000 units in 2026, Johnson & Johnson GmbH offers comprehensive training modules to healthcare professionals, ensuring the safe and effective use of biosimilar products.
18. Sanofi-Aventis Deutschland GmbH
Sanofi-Aventis Deutschland GmbH is a subsidiary of Sanofi, a global pharmaceutical company that focuses on the development and commercialization of biosimilar drugs. With a trade value of $30 million in 2026, Sanofi-Aventis Deutschland GmbH provides valuable training modules to healthcare professionals, enhancing their knowledge and skills in biosimilar therapy.
19. Eli Lilly GmbH
Eli Lilly GmbH is a subsidiary of Eli Lilly and Company, a leading pharmaceutical company with a strong presence in the biosimilars market. With exports worth $40 million in 2026, Eli Lilly GmbH offers innovative training modules to healthcare professionals, supporting the successful implementation of biosimilar therapies.
20. Roche Deutschland Holding GmbH
Roche Deutschland Holding GmbH is a subsidiary of Roche, a multinational healthcare company that is actively involved in the development of biosimilar drugs. With a market share of 5% in the training modules sector, Roche Deutschland Holding GmbH offers state-of-the-art educational resources to support healthcare professionals in adopting biosimilar therapies.
Insights:
The biosimilars market in Germany is poised for significant growth in 2026, driven by the increasing demand for cost-effective alternatives to biologic drugs. With a projected market size of $2.5 billion by 2026, Germany remains a key player in the global biosimilars market. As pharmaceutical companies continue to invest in the development and commercialization of biosimilar drugs, the demand for high-quality training modules for healthcare professionals is expected to rise. By offering comprehensive educational resources and innovative training programs, companies can support the successful adoption of biosimilar therapies and contribute to the growth of the biosimilars market in Germany and beyond.
Related Analysis: View Previous Industry Report
